YARNO WENDY L 4

What Happened Wendy L. Yarno, a director of Inovio Pharmaceuticals (INO), was granted a total of 76,000 derivative awards on May 20, 2026: 41,800 option-type awards and 34,200 restricted stock units (RSUs). Both grants have an acquisition price of $0.00 on the Form 4 (no cash paid). According to the filing, these awards were made under Inovio’s 2023 Omnibus Incentive Plan pursuant to the company’s non-employee director compensation policy. The awards vest 100% on May 20, 2027.

Key Details

• Transaction date: May 20, 2026; Form 4 filed May 21, 2026 (filed the next day).
• Instruments and amounts: 41,800 option awards (derivative) and 34,200 RSUs (derivative), total 76,000 awards.
• Price: $0.00 per award (no cash exchanged at grant).
• Vesting: Both sets vest 100% on May 20, 2027 (per footnotes).
• Plan/authority: Granted under the 2023 Omnibus Incentive Plan as part of the non-employee director compensation policy.
• Shares owned after transaction: Not disclosed in the provided filing.

Context

• The filing shows grants (award/derivative grants), not open-market purchases or sales — these are routine director compensation rather than an insider buying stock on the market.
• The RSUs represent contingent rights to receive common stock upon vesting; the option-type awards likewise vest in full on the stated date. There’s no indication shares were sold or exercised at the time of grant.
• Filing was timely (reported the day after the grant).